



Correction

Correction: Rojas-Peña et al. Individualized Transcriptional Resolution of Complicated Malaria in a Colombian Study. *J. Pers. Med.* 2018, 8, 29

Mónica L. Rojas-Peña 1,† , Meixue Duan 1,† , Dalia Arafat 1 , Lina Rengifo 2 , Socrates Herrera 2 , Myriam Arévalo-Herrera 2,‡ and Greg Gibson 1,*,‡

- Center for Integrative Genomics, Georgia Institute of Technology, Atlanta, GA 30332, USA; monicarojasp@gmail.com (M.L.R.-P.); mduan31@gatech.edu (M.D.); darafat.gt@gmail.com (D.A.)
- ² CAUCASECO, Cali, Colombia; lrengifo@inmuno.org (L.R.); sherrera@inmuno.org (S.H.); marevalo@inmuno.org (M.A.-H.)
- * Correspondence: greg.gibson@biology.gatech.edu; Tel.: +1-404-385-2343
- [†] These authors contributed equally as first authors.
- [‡] These authors contributed equally as senior authors.

In the original publication [1], the ethical approval code and date information was missing. This has now been revised to Section 2.1 "Study Design and Subject Recruitment", the last sentence of the paragraph and added to the Institutional Review Board Statement at the Back Matter of the paper.

The corrected statement appears below.

"All patients provided written informed consent for participation before enrolment, and the study protocol was approved by the Institutional Review Board (IRB) for the Malaria Vaccine and Drug Development Center (CECIV Approval letter 1.0) with DMID protocol 13-0056 on 14 February 2014, also amended on 1 October 2014 (Version 2.0) and 27 January 2016 (Version 3.0). In addition, the Georgia Institute of Technology IRB provided subsequent approval for genomic analyses on 4 April 2014, Amendment #1 to protocol H13495."

The Institutional Review Board Statement appears below.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board for the Malaria Vaccine and Drug Development Center (CECIV Approval letter 1.0) with DMID protocol 13-0056 on 14 February 2014, also amended on 1 October 2014 (Version 2.0) and 27 January 2016 (Version 3.0). In addition, the Georgia Institute of Technology IRB provided subsequent approval for genomic analyses on 4 April 2014, Amendment #1 to protocol H13495.

The authors state that these corrections do not impact the overall findings and conclusions of the paper. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

 Rojas-Peña, M.L.; Duan, M.; Arafat, D.; Rengifo, L.; Herrera, S.; Arévalo-Herrera, M.; Gibson, G. Individualized Transcriptional Resolution of Complicated Malaria in a Colombian Study. J. Pers. Med. 2018, 8, 29. [CrossRef] [PubMed]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.



Citation: Rojas-Peña, M.L.; Duan, M.; Arafat, D.; Rengifo, L.; Herrera, S.; Arévalo-Herrera, M.; Gibson, G. Correction: Rojas-Peña et al. Individualized Transcriptional Resolution of Complicated Malaria in a Colombian Study. *J. Pers. Med.* 2018, 8, 29. *J. Pers. Med.* 2024, 14, 1060. https://doi.org/10.3390/jpm14101060

Received: 17 September 2024 Accepted: 20 September 2024 Published: 14 October 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).